AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8678516
Drug: Leucovorin (LV,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leucovorin (LV, 30 mg/body) + 5‐fluorouracil (5‐FU 500 ‐ 750 mg/body) administered via intra‐hepatic artery injection
Trial: 31880795
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of GRS and family history (FH)
Trial: 25799001
Drug: WhatsApp chat
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: WhatsApp chat room-based competition for oral hygiene compliance
Trial: 25799001
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard oral hygiene instructions without app)
Trial: 19279226
Drug: Methylprednisolone plus
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone plus lidocaine (steroid)
Trial: 17559628
Drug: Experimental gingivitis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental gingivitis (initial prophylaxis followed by total neglect of oral hygiene)
Trial: 17559628
Drug: Persistent gingivitis
RxNorm normalized name: BD Persist
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Persistent gingivitis (continued habitual insufficient oral hygiene)
Trial: 15159285
Drug: Prednisolone 20
RxNorm normalized name: prednisolone 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 20 mg/day for three months, with tapering dose in month 4, plus multidrug treatment
Trial: 15159285
Drug: Multidrug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidrug treatment alone
Trial: 28707987
Drug: Caffeine treatment
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine treatment
Trial: 28249684
Drug: LMA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LMA with subparalytic dose of MR (group 3)
Trial: 25403334
Drug: Rhodiola crenulata
RxNorm normalized name: RHODIOLA CRENULATA ROOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhodiola crenulata 500 mg daily for 12 weeks
Trial: 25403334
Drug: Placebo (starch/phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (starch/phosphate buffered saline) daily for 12 weeks
Trial: 18081753
Drug: Dapsone +
RxNorm normalized name: Dapsone
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dapsone + desloratadine (10 mg daily)
Trial: 18081753
Drug: Desloratadine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desloratadine (10 mg daily)
Trial: 1862893
Drug: bupivacaine 0.5%
RxNorm normalized name: BUPivacaine 0.5% injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine 0.5% 8 ml initial dose with fentanyl 0.0002%
Trial: 6641089
Drug: Low-dose perhexiline
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose perhexiline during exercise training
Trial: 6641089
Drug: Low-dose perhexiline
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose perhexiline
Trial: 28914700
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of IV ketorolac
Trial: 28185214
Drug: Lipoprotein apheresis
RxNorm normalized name: Zaire ebolavirus envelope glycoprotein Injection [Ervebo]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipoprotein apheresis (LA), regular LA treatment over 5 years
Trial: 20853269
Drug: 1.25 mg
RxNorm normalized name: menthol 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg intravitreal bevacizumab at the end of surgery
Trial: 16368284
Drug: Oral anticoagulants
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulants (OAC) plus antiplatelet therapy
Trial: 9092958
Drug: Topiramate (TPM)
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate (TPM) at target daily dosages of up to 9 mg/kg/day
Trial: 9092958
Drug: Adjunctive TPM
RxNorm normalized name: TPM
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adjunctive TPM therapy
Trial: 9092958
Drug: TPM monotherapy
RxNorm normalized name: TPM
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: TPM monotherapy substitution
Trial: 8403580
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid (HA), 7 injections over 6 weeks
Trial: 8403580
Drug: Mucopolysaccharide polysulfuric
RxNorm normalized name: sulfated mucopolysaccharides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mucopolysaccharide polysulfuric acid ester (MPA), 13 injections over 6 weeks
Trial: 29975728
Drug: Protein-reduced infant
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein-reduced infant formula (1.89 g protein/100 kcal) with alpha-lactalbumin enriched whey and long-chain polyunsaturated fatty acids (LC-PUFA)
Trial: 29975728
Drug: Standard formula
RxNorm normalized name: Standard formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard formula (2.2 g protein/100 kcal) without LC-PUFA
Trial: 24615094
Drug: Remifentanil (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (target plasma concentration 3 ng/mL)
Trial: 24615094
Drug: Propofol (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (target plasma concentration 2 μg/mL)
Trial: 18398095
Drug: High-dose ICE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ICE chemotherapy (ifosfamide, carboplatin, etoposide) with PBPC support
Trial: 18398095
Drug: Standard-dose ICE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose ICE chemotherapy (ifosfamide, carboplatin, etoposide)
Trial: 18398095
Drug: High-dose ICE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ICE chemotherapy
Trial: 18398095
Drug: Standard-dose ICE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose ICE chemotherapy
Trial: 15068496
Drug: simvastatin 40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: simvastatin 40 mg/day
Trial: 16872244
Drug: ezetimibe 10
RxNorm normalized name: ezetimibe 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ezetimibe 10 mg/day plus simvastatin 40 mg/day
Trial: 14635608
Drug: Diuretics (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretics (in males)
Trial: 14635608
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment (phase 1)
Trial: 8615470
Drug: Preoperative combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative combination treatment (radiation, intraluminal hyperthermia, and 5-fluorouracil suppositories)
Trial: 8615470
Drug: Surgery after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery after preoperative combination treatment
Trial: 3805328
Drug: Lithium treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium treatment (0.8 mEq/liter for 1 week)
Trial: 29971998
Drug: Auricular point
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auricular point sticking therapy at bilateral shenmen (TF4), pizhixia (AT4), jiaogan (AH6a) and gangmen (HX5), pressing 3-6 times every day, once 3-5 min.
Trial: 29971998
Drug: Combined group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined group (EA + auricular point sticking therapy).
Trial: 25339836
Drug: Split-dose of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split-dose of 2-litre PEG-ELS
Trial: 25339836
Drug: Whole-dose of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-dose of 2-litre PEG-ELS
Trial: 12140209
Drug: Hypotonic (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypotonic (150 mOsm/l) 0.4% hyaluronate eye drops
Trial: 9656236
Drug: IL‐2, LAK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL‐2, LAK adoptive immunotherapy
Trial: 7654922
Drug: Self-medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-medication
Trial: 7654922
Drug: Self-medication with
RxNorm normalized name: chloroxylenol Medicated Pad [E-Z Scrub with Ultradex]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-medication with antibiotics
Trial: 7654922
Drug: Self-medication with
RxNorm normalized name: chloroxylenol Medicated Pad [E-Z Scrub with Ultradex]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-medication with vitamins
Trial: 7654922
Drug: Self-medication for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-medication for asthenia
Trial: 7654922
Drug: Previous medical
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Previous medical prescription
Trial: 2647677
Drug: Any preparatory
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any preparatory treatment
Trial: 12138261
Drug: Steroid pulse
RxNorm normalized name: dulse extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid pulse therapy (steroid pulse group)
Trial: 31424972
Drug: Tailored DAA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored DAA treatment based on baseline resistance findings, including prolonged treatment duration of NS5A-inhibitor and sofosbuvir (SOF) and/or addition of ribavirin (RBV) for patients with baseline Y93H.
Trial: 31424972
Drug: Standard DAA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard DAA treatment for patients without baseline Y93H and all patients in the control group.
Trial: 31424972
Drug: Personalized treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized treatment for patients with baseline Y93H in the intervention group.
Trial: 31424972
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment for patients with baseline Y93H in the control group.
Trial: 15731561
Drug: Progestin therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progestin therapy
Trial: 9793946
Drug: Retrobulbar anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retrobulbar anesthesia (4 cc of a 50:50 mixture of 2% xylocaine and 0.75% bupivacaine with 150 units of hyaluronidase)
Trial: 9793946
Drug: Peribulbar anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peribulbar anesthesia (6 cc of a 50:50 mixture of 2% xylocaine and 0.75% bupivacaine with 150 units of hyaluronidase)
Trial: 2565416
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg bd tazifylline
Trial: 1052162
Drug: Pentoxifylline (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (200 mg intravenous infusion)
Trial: 27376907
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution (10 ml)
Trial: 31669091
Drug: 1% iodine
RxNorm normalized name: 1% Iodine Tincture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% iodine solution (group A)
Trial: 31669091
Drug: 2% iodine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% iodine solution (group B)
Trial: 28481882
Drug: 800 IU
RxNorm normalized name: Vitamin E 800 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 IU vitamin D3 daily for 6 months (Supplementation Study)
Trial: 28481882
Drug: 300 IU
RxNorm normalized name: Follistim AQ 300 IU per 0.36 ML Cartridge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 IU vitamin D3 daily in fortified milk for 7 weeks (Fortification Study)
Trial: 25297721
Drug: Topical clobetasol
RxNorm normalized name: clobetasol Topical Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical clobetasol propionate cream (0.05%) applied at home
Trial: 25297721
Drug: Topical silver
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical silver nitrate (99%) in the outpatient clinic
Trial: 21771340
Drug: No-treatment control
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-treatment control group.
Trial: 16338019
Drug: Amantadine 100
RxNorm normalized name: amantadine 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amantadine 100 mg twice daily for 48 weeks
Trial: 14984391
Drug: Integrated treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated treatment with cognitive‐behaviour therapy and coping training
Trial: 8434556
Drug: Probucol 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probucol 0.5 g twice daily
Trial: 27650295
Drug: Palonosetron plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palonosetron plus TIVA (palonosetron 0.075 mg i.v.)
Trial: 27650295
Drug: TIVA (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIVA (normal saline 1.5 ml i.v.)
Trial: 28560383
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg genistein daily for 3-6 weeks
Trial: 10595786
Drug: Lutein (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutein (15 mg/day)
Trial: 8951132
Drug: Intracervical prostaglandin
RxNorm normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracervical prostaglandin E2 (PGE2) gel (0.5 mg) followed by insertion of a 24-Foley catheter
Trial: 8951132
Drug: Intracervical prostaglandin
RxNorm normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracervical prostaglandin E2 (PGE2) gel (two doses of 0.5 mg)
Trial: 2021677
Drug: Alcohol ingestion
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol ingestion (two dosage levels)
Trial: 27605038
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of calorie restriction and exercise (7% weight loss over 3-6 months)
Trial: 27281448
Drug: Ambroxol Lozenges
RxNorm normalized name: ambroxol
DrugBank: Ambroxol (DB06742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambroxol Lozenges (AXL20) 20mg
Trial: 27281448
Drug: Placebo Lozenges
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Lozenges (PL)
Trial: 22983495
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of features from multiple ERP components
Trial: 19572937
Drug: Paracetamol 2
RxNorm normalized name: Paracetamol 24 mg/mL oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 2 g
Trial: 7981460
Drug: Droloxifene 20
RxNorm normalized name: Droloxifene
DrugBank: Droloxifene (DB15641)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droloxifene 20 mg daily
Trial: 7981460
Drug: Droloxifene 40
RxNorm normalized name: Droloxifene
DrugBank: Droloxifene (DB15641)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droloxifene 40 mg daily
Trial: 7981460
Drug: Droloxifene 100
RxNorm normalized name: Droloxifene
DrugBank: Droloxifene (DB15641)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droloxifene 100 mg daily
Trial: 23704673
Drug: Metformin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin alone (M)
Trial: 23704675
Drug: Metformin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin plus intensive lifestyle program (M+L)
Trial: 23704673
Drug: Metformin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin plus rosiglitazone (M+R)
Trial: 23704675
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (M, M+R, M+L)
Trial: 17909125
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (fluoxetine + CBT)
Trial: 20631556
Drug: Fluoxetine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine therapy
Trial: 15911154
Drug: Behavioural medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioural medicine rehabilitation (PT+CBT)
Trial: 15911154
Drug: Treatment-as-usual control
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual control group (CG)
Trial: 11306379
Drug: MMP-2 excretion
RxNorm normalized name: SNAIL SECRETION FILTRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMP-2 excretion
Trial: 11306379
Drug: MMP-9 excretion
RxNorm normalized name: SNAIL SECRETION FILTRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMP-9 excretion
Trial: 9330417
Drug: MDI albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDI albuterol through a neonatal Aerochamber with non-rebreathing valve
Trial: 9330417
Drug: MDI albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDI albuterol through a neonatal Aerochamber without non-rebreathing valve
Trial: 9330417
Drug: MDI albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDI albuterol through Babyhaler with one-way inspiratory valve
Trial: 9330417
Drug: MDI albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDI albuterol through Babyhaler without one-way inspiratory valve
Trial: 22527287
Drug: Dietary supplement
RxNorm normalized name: dietary supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplement (DS) containing Red yeast rice (RYR), sugar cane‐derived policosanols (SCdP), and artichoke leaf extracts (ALEs)
Trial: 10385662
Drug: Prolonged therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged therapy (IFN‐alpha for up to 32 weeks)
Trial: 10385662
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (IFN‐alpha for 16 weeks)
Trial: 6441537
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg piribedil intravenously over a 15 min period
Trial: 6441537
Drug: Dopamine receptor
RxNorm normalized name: Dopamine receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine receptor blocking agent, haloperidol (pretreated group)
Trial: 20006921
Drug: Z‐360 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Z‐360 120 mg
Trial: 20006921
Drug: Z‐360 240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Z‐360 240 mg
Trial: 20006921
Drug: Z‐360 (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Z‐360 (both doses)
Trial: 14727947
Drug: Ezetimibe plus
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe plus a statin (lovastatin, pravastatin, atorvastatin, or simvastatin)
Trial: 441686
Drug: High dosage
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dosage of fluphenazine enanthate
Trial: 441686
Drug: Low dosage
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dosage of fluphenazine enanthate
Trial: 17823681
Drug: Co-curing the
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Co-curing the bonding agent with resin composite (Group COC)
Trial: 11529355
Drug: Zidovudine (ZDV)
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine (ZDV) treatment: 250 mg ZDV orally twice a day starting at 38 weeks' gestation until labor, plus ZDV infusion at 2 mg/kg during the first hour of labor and then 1 mg/kg/h until delivery.
Trial: 11529355
Drug: Placebo treatment:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment: identical capsule during pregnancy and normal saline infusion during labor until delivery.
Trial: 7461330
Drug: Initial 'empiric'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial 'empiric' dosage followed by 'rational' maintenance (group IV)
Trial: 31888691
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) intervention (Fear Reduction Efficacy Evaluation [FREE]) for 8 weeks, consisting of 8 weekly individual one-hour sessions.
Trial: 31888691
Drug: Attention control
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Attention control group receiving diabetes self-management education (DSME) for 8 weeks, consisting of 8 weekly individual one-hour sessions.
Trial: 31888691
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) intervention (FREE)